Therachon SAS
Records under this name other than patents Therachon SAS holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Therachon SAS
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,294,289 | Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides and Uses Thereof now held by Pfizer Inc. In force · High confidence | In force | High confidence | |
| US 11,021,528 | Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides and Uses Thereof now held by Pfizer Inc. Lapsed on the fee record Ended Jun 1, 2025 · High confidence | Lapsed on the fee record | Ended Jun 1, 2025 | High confidence |
| 15/541,993 | Soluble FGFR3 Decoys for Treating Skeletal Growth Disorders now held by Pfizer Inc. Abandoned Abandoned Mar 2, 2020 | Abandoned | Abandoned Mar 2, 2020 | |
| 16/649,208 | Treatment of Abnormal Visceral Fat Deposition Using Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides now held by Pfizer Inc. Abandoned Abandoned Nov 4, 2022 | Abandoned | Abandoned Nov 4, 2022 | |
| 16/796,666 | Soluble FGFR3 Decoys for Treating Skeletal Growth Disorders now held by Pfizer Inc. Abandoned Abandoned Feb 21, 2024 | Abandoned | Abandoned Feb 21, 2024 |